Introduction Executive Summary Fibrodysplasia ossificans progressiva: Overview • Causes • Mechanism of Action • Signs and Symptoms • Diagnosis • Disease Management Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Fibrodysplasia ossificans progressiva – DelveInsight’s Analytical Perspective Late Stage Products (Preregistration) • Comparative Analysis Palovarotene: Ipsen • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis BLU 782: Blueprint Medicines • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis DS 6016: Daiichi Sankyo • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Fibrodysplasia ossificans progressiva Key Companies Fibrodysplasia ossificans progressiva Key Products Fibrodysplasia ossificans progressiva- Unmet Needs Fibrodysplasia ossificans progressiva- Market Drivers and Barriers Fibrodysplasia ossificans progressiva- Future Perspectives and Conclusion Fibrodysplasia ossificans progressiva Analyst Views Fibrodysplasia ossificans progressiva Key Companies Appendix

Table 1 Total Products for Fibrodysplasia ossificans progressiva Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Ipsen • Blueprint Medicines • Regeneron Pharmaceuticals • Daiichi Sankyo, Inc. • AstraZeneca • Incyte Corporation • Keros Therapeutics • BioCryst Pharmaceuticals